A phase III randomized of Cloretazine (VNP40101M) [laromustine] and cytosine arabinoside (AraC) [cytarabine] in patients with acute myeloid leukemia in first relapse.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2013

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12606000514505).
29 Dec 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
05 Nov 2009 Results reported in Blood.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com